Sedation-Pipeline Review, H1 2015

Sedation-Pipeline Review, H1 2015

  • Products Id :- GMDHC6091IDB
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sedation-Pipeline Review, H1 2015


Global Markets Direct's, 'Sedation-Pipeline Review, H1 2015', provides an overview of the Sedation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Sedation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Sedation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Sedation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Sedation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Sedation Overview 6

Therapeutics Development 7

Pipeline Products for Sedation-Overview 7

Pipeline Products for Sedation-Comparative Analysis 8

Sedation-Therapeutics under Development by Companies 9

Sedation-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Unknown Stage Products 13

Sedation-Products under Development by Companies 14

Sedation-Companies Involved in Therapeutics Development 15

Advicenne Pharma 15

AstraZeneca PLC 16

Maruishi Pharmaceutical Co., Ltd. 17

NanoMedex Pharmaceuticals, Inc. 18

Paion AG 19

Sedation-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 28

ABP-700-Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ADV-6209-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

clonidine hydrochloride-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

MR-04A3-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

propofol-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

propofol Microemulsion-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

remimazolam-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Sedation-Recent Pipeline Updates 37

Sedation-Dormant Projects 40

Sedation-Discontinued Products 41

Sedation-Product Development Milestones 42

Featured News & Press Releases 42

Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 42

Oct 10, 2014: Paion Expects Ono'S Remimazolm Decision On Filing In Japan In November 2014 42

Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 43

Aug 11, 2014: Diprivan (Propofol) Injectable Emulsion, USP Now Available in 10 mL Vials 44

Nov 23, 2013: PAION announces positive End-of-Phase II Meeting with FDA for Remimazolam in procedural sedation 45



May 08, 2013: Paion's Partner Ono Pharma Completes Recruitment For Phase II/III Study Of Remimazolam For General Anesthesia 46

Dec 18, 2012: Paion Receives $3m Milestone Payment From Ono Pharma Following Enrollment Of First Patient In Phase II/III Study Of Remimazolam 46

Nov 05, 2012: Paion's Partner Ono Pharma Intiates Phase II/III Study With Short-acting Anaesthetic/Sedative Remimazolam In Japan 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 49

Disclaimer 49

List of Tables

Number of Products under Development for Sedation, H1 2015 7

Number of Products under Development for Sedation-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Comparative Analysis by Early Stage Development, H1 2015 12

Comparative Analysis by Unknown Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Sedation-Pipeline by Advicenne Pharma, H1 2015 15

Sedation-Pipeline by AstraZeneca PLC, H1 2015 16

Sedation-Pipeline by Maruishi Pharmaceutical Co., Ltd., H1 2015 17

Sedation-Pipeline by NanoMedex Pharmaceuticals, Inc., H1 2015 18

Sedation-Pipeline by Paion AG, H1 2015 19

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Stage and Target, H1 2015 22

Number of Products by Stage and Mechanism of Action, H1 2015 24

Number of Products by Stage and Route of Administration, H1 2015 26

Number of Products by Stage and Molecule Type, H1 2015 27

Sedation Therapeutics-Recent Pipeline Updates, H1 2015 37

Sedation-Dormant Projects, H1 2015 40

Sedation-Discontinued Products, H1 2015 41

List of Figures

Number of Products under Development for Sedation, H1 2015 7

Number of Products under Development for Sedation-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Top 10 Targets, H1 2015 21

Number of Products by Stage and Top 10 Targets, H1 2015 22

Number of Products by Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24

Number of Products by Top 10 Routes of Administration, H1 2015 25

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25

Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Advicenne Pharma

AstraZeneca PLC

Maruishi Pharmaceutical Co., Ltd.

NanoMedex Pharmaceuticals, Inc.

Paion AG

Sedation Therapeutic Products under Development, Key Players in Sedation Therapeutics, Sedation Pipeline Overview, Sedation Pipeline, Sedation Pipeline Assessment

select a license

Single User License
USD 2000 INR 133840
Site License
USD 4000 INR 267680
Corporate User License
USD 6000 INR 401520



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]